Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a r...
NetworkNewsWire Editorial Coverage : Gene therapy is hot on the trail of killing cancer, and companies that deliver cures could see blockbuster returns. Pioneering a new paradigm in cancer therapeutics, Genprex Inc. (NASDAQ: GNPX) ( GNPX Profile ) is leveraging its patented technology pla...
RESEARCH TRIANGLE PARK, N.C., May 16, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that additional findings from a Phase 2 clinical trial demonstrating the myelopreservation benefits of trilaciclib in 2 nd /3 rd -line smal...
RESEARCH TRIANGLE PARK, N.C., May 13, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company overview at the UBS Global Healthcare Conference. The present...
G1 Therapeutics, Inc. (GTHX) Q1 2019 Earnings Conference Call May 9, 2019 16:30 ET Company Participants Jeff Macdonald - Head, Investor & Public Relations Mark Velleca - President & CEO Jennifer Moses - CFO Rajesh Malik - Chief Medical Officer & SVP R&D Confe...
Gainers: Charles & Colvard (NASDAQ: CTHR ) +34% . Buckeye Partners (NYSE: BPL ) +28% . Cardlytics (NASDAQ: CDLX ) +26% . G1 Therapeutics (NASDAQ: GTHX ) +24% . Westport Fuel Systems (NASDAQ: WPRT ) +21% . Cool Holdings (NASDAQ: AWSM ) +22% . Guardant Health (NASDAQ: GH ) +...
G1 Therapeutics ( GTHX +22.1% ) is up on modestly higher volume in early trade following its Q1 report released after the close yesterday. Investors appear to like its progress with trilaciclib and pipeline progress. More news on: G1 Therapeutics, Inc., Healthcare stocks news, Stocks o...
G1 Therapeutics (NASDAQ: GTHX ): Q1 GAAP EPS of -$0.64 beats by $0.08 . Cash and equivalents of $347.8M. Press Release More news on: G1 Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Plans to submit U.S. and European marketing applications for trilaciclib following regulatory feedback First clinical data on oral SERD G1T48 expected in 3Q19 Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE ...
G1 Therapeutics Inc. ( GTHX ) announced that it had achieved a positive end of phase 2 meeting with the FDA with its drug trilaciclib for myelopreservation in small cell lung cancer ((SCLC)). The biotech also has a few other drugs that it is working on that could potentially be an improvem...
News, Short Squeeze, Breakout and More Instantly...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 AD...
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today a...